LINC00926: A Potential Drug Target and Biomarker for Cancer (G283663)

Target Name: LINC00926

NCBI ID: G283663

LINC00926

Other Name(s): Long intergenic non-protein coding RNA 926 | long intergenic non-protein coding RNA 926

LINC00926: A Potential Drug Target and Biomarker for Cancer

LINC00926 is a non-coding RNA (ncRNA) that is located between the genes HO-1 and miRNA-1246. It is a potential drug target and has been identified as a potential biomarker for several diseases, including cancer.

The discovery and characterization of LINC00926 was made by a team of researchers at the University of California, San Diego (UCSD). The researchers used RNA sequencing (RNA-seq) to identify the ncRNA in the gene that corresponds to LINC00926. They found that LINC00926 is a highly conserved non-coding RNA that is expressed in a variety of tissues and organs, including brain, heart, and muscle.

The next step for the researchers was to determine the function of LINC00926. They used a variety of techniques to study the RNA levels and stability of LINC00926 in different cell types and tissues. They found that LINC00926 is highly expressed in brain and muscle tissue, and that it is significantly downregulated in cancer cells.

The researchers also used functional assays to determine the potential functions of LINC00926. They found that LINC00926 is involved in the regulation of cell growth, and that it can inhibit the activity of a protein called p21, which promotes cell growth. They also found that LINC00926 is involved in the regulation of cell apoptosis, and that it can induce cell death in cancer cells.

The researchers conclude that LINC00926 is a promising drug target and has the potential to be used as a biomarker for cancer. They are currently working to develop methods for introducing LINC00926 into cancer cells as a new treatment strategy.

In addition to its potential as a drug target, LINC00926 also has the potential as a biomarker for cancer. The researchers found that LINC00926 is downregulated in cancer cells, and that it can be used as a marker for the disease. They are currently working to develop methods for using LINC00926 as a diagnostic biomarker for cancer.

Overall, the discovery and characterization of LINC00926 is a significant step forward in the understanding of the biology of this ncRNA and its potential as a drug target and biomarker. Further research is needed to fully understand the functions of LINC00926 and its potential as a new treatment and diagnostic tool.

Protein Name: Long Intergenic Non-protein Coding RNA 926

The "LINC00926 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00926 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets